Outcome of the Board Meeting held on Thursday, 14th August, 2025.
BLACKROSE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Black Rose Industries' board approved standalone and consolidated unaudited results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations fell to ₹59.85 crore from ₹74.18 crore a year ago (down ~19%), while PAT declined to ₹4.24 crore from ₹4.68 crore; EPS stood at ₹0.83 vs ₹0.82 (basic, consolidated). Consolidated revenue dropped sharply to ₹59.85 crore from ₹98.27 crore (~39% decline), largely because the Japan subsidiary (B.R. Chemicals Co. Ltd) had already discontinued operations from January 30, 2025. The board approved the closure, sale, or transfer of its 100% stake in the Japan subsidiary, which contributed 13.6% of consolidated income last year. The 35th AGM is scheduled for September 29, 2025 via video conferencing. Additionally, CFO Ratan Agrawal was appointed as Chief Risk Officer, two senior management personnel were designated, and a new secretarial auditor was appointed for a 5-year term.
The headline revenue decline on a consolidated basis is driven mainly by the Japan subsidiary wind-down, which the company had already flagged. Investors should focus on standalone performance, where revenue dipped ~19% but margins and absolute profitability remained broadly stable, suggesting underlying business resilience despite the top-line softness.